報價延遲最少15分鐘:2026/09/04 01:14 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.77 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.44/-0.11
|
|
企業價值
2.48B
|
| 資產負債 |
|
每股賬面淨值
0.72
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
62.90M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan. |
